---
title: "China's Sciwind Biosciences: GLP-1 drug approved by China's National Medical Products Administration"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274251916.md"
description: "China's Sciwind Biosciences: GLP-1 drug approved by China's National Medical Products Administration"
datetime: "2026-01-30T05:12:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274251916.md)
  - [en](https://longbridge.com/en/news/274251916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274251916.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274251916.md) | [繁體中文](https://longbridge.com/zh-HK/news/274251916.md)


# China's Sciwind Biosciences: GLP-1 drug approved by China's National Medical Products Administration



### 相关股票

- [Spruce Biosciences (SPRB.US)](https://longbridge.com/zh-CN/quote/SPRB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [MBX Biosciences (MBX.US)](https://longbridge.com/zh-CN/quote/MBX.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)

## 相关资讯与研究

- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/zh-CN/news/278530484.md)
- [BUZZ-Erasca rises on partnership with Tango to test new cancer drug combo](https://longbridge.com/zh-CN/news/277972424.md)
- [Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study](https://longbridge.com/zh-CN/news/278381816.md)
- [Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0) M Net Loss](https://longbridge.com/zh-CN/news/278384128.md)
- [AbbVie's ABBV-295 Shows Strong Weight Loss Results in Phase 1 Trial](https://longbridge.com/zh-CN/news/278398258.md)